Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas.
about
CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrestDual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
P2860
Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Dual inhibition of CDK4/Rb and ...... lity in mantle cell lymphomas.
@ast
Dual inhibition of CDK4/Rb and ...... lity in mantle cell lymphomas.
@en
type
label
Dual inhibition of CDK4/Rb and ...... lity in mantle cell lymphomas.
@ast
Dual inhibition of CDK4/Rb and ...... lity in mantle cell lymphomas.
@en
prefLabel
Dual inhibition of CDK4/Rb and ...... lity in mantle cell lymphomas.
@ast
Dual inhibition of CDK4/Rb and ...... lity in mantle cell lymphomas.
@en
P2093
P2860
P356
P1433
P1476
Dual inhibition of CDK4/Rb and ...... lity in mantle cell lymphomas.
@en
P2093
A C Antonelli
E Premkumar Reddy
M V Ramana Reddy
S C Cosenza
S K A Divakar
P2860
P2888
P356
10.1038/LEU.2015.185
P577
2015-07-15T00:00:00Z